A recent study demonstrated the efficacy of a humanized anti-OPN antibody in inhibiting breast cancer growth and metastasis in vivo [42], the efficacy of targeting OPN in CRC treatment by this anti-OPN antibody or other inhibitors warrants further investigations. This evidence concerns the gene SPP1 and breast carcinoma.